- CRS Publications
- News
News
Date:
PRNewswire: March 23, 2017 – BOSTON, MA, U.S.A. – Newborns are highly vulnerable to infections and don’t respond optimally to most vaccines because their young immune systems typically mount weak antibody responses. Now, researchers at Boston Children’s Hospital report achieving strong vaccine…
Authors:
Date:
PRNewswire: March 23, 2017 – CAMBRIDGE, MA, U.S.A. – Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced the enrollment of its first patient in a phase 1 study of MM-310 in solid tumors. MM-310 is an antibody-directed nanotherapeutic (ADN) that encapsulates a novel taxane and targets the…
Authors:
Date:
PRNewswire: March 22, 2017 – JERUSALEM, Israel – Intec Pharma Ltd. (Nasdaq; TASE: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces the initiation of a phase I clinical trial of AP-CBD/THC, its…
Authors:
Date:
PRNewswire: March 14, 2017 – LUND, Sweden – Bonesupport AB, an emerging leader in innovative injectable bioceramic bone scaffolds to treat bone voids caused by trauma, infection, disease, or related surgery, announces that it has extended the term of its U.S. distribution agreement with Zimmer…
Authors:
Date:
PRNewswire: March 14, 2017 – SAN DIEGO, CA, U.S.A. – OncoSec Medical Incorporated (“OncoSec”) (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that they have entered into a technology access program (TAP) agreement with Inhibrx, LP, a privately…
Authors:
Date:
Business Wire: March 14, 2017 – BOSTON, MA, U.S.A., and MUMBAI, India – TA Associates, a leading global growth private equity firm, today announced it has completed an investment in Ideal Cures Private Limited, a supplier of ready-to-use coating products and excipients for tablets and capsules to…
